PI3K/mTOR Pathway Inhibitors: Mechanisms and Therapeutic Applications

# PI3K/mTOR Pathway Inhibitors: Mechanisms and Therapeutic Applications

Introduction to the PI3K/mTOR Pathway

The PI3K/mTOR pathway is a crucial intracellular signaling network that regulates various cellular processes, including cell growth, proliferation, metabolism, and survival. This pathway has gained significant attention in cancer research due to its frequent dysregulation in human malignancies. The pathway consists of two main components: phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), which work together to transmit signals from growth factors and nutrients to downstream effectors.

Mechanisms of PI3K/mTOR Pathway Activation

Activation of the PI3K/mTOR pathway typically begins with the binding of growth factors to receptor tyrosine kinases (RTKs). This binding triggers PI3K activation, which converts phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 then recruits Akt to the plasma membrane, where it becomes phosphorylated and activated. Activated Akt subsequently phosphorylates numerous downstream targets, including mTOR complex 1 (mTORC1), which serves as a central regulator of cell growth and metabolism.

Rationale for Targeting the PI3K/mTOR Pathway

The PI3K/mTOR pathway is frequently hyperactivated in cancer through various mechanisms, including:

PIK3CA mutations (encoding the p110α catalytic subunit of PI3K)

PTEN loss or mutation (a negative regulator of the pathway)

Amplification or mutation of upstream receptors (e.g., HER2, EGFR)

Activating mutations in Akt or mTOR

These alterations make the PI3K/mTOR pathway an attractive therapeutic target for cancer treatment.

Classes of PI3K/mTOR Pathway Inhibitors

1. PI3K Inhibitors

PI3K inhibitors can be classified based on their specificity:

Pan-PI3K inhibitors: Target all class I PI3K isoforms (e.g., Buparlisib)

Keyword: PI3K mTOR pathway inhibitors

Isoform-selective inhibitors: Target specific PI3K isoforms (e.g., Alpelisib for p110α)

Dual PI3K/mTOR inhibitors: Target both PI3K and mTOR (e.g., Dactolisib)

2. mTOR Inhibitors

mTOR inhibitors fall into two main categories:

Rapalogs: Allosteric inhibitors of mTORC1 (e.g., Everolimus, Temsirolimus)

ATP-competitive mTOR inhibitors: Target the kinase domain of both mTORC1 and mTORC2 (e.g., Sapanisertib)

Therapeutic Applications

Oncology

PI3K/mTOR inhibitors have shown clinical activity in various cancers:

Breast cancer (Alpelisib for PIK3CA-mutant HR+/HER2- breast cancer)

Renal cell carcinoma (Everolimus, Temsirolimus)

Lymphoma (Copanlisib for relapsed follicular lymphoma)

Endometrial cancer (Everolimus in combination with letrozole)

Evizda